Creating a prediction platform for treatment and prognosis in pancreatic cancer using organoids
Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Pancreatic Cancer Using Ex Vivo Analysis of Organoid Culture
This study is testing if lab-grown mini tumors from pancreatic cancer patients can help doctors choose the best chemotherapy after surgery based on how these tumors respond to different drugs.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Samsung Medical Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Seoul) |
| Trial ID | NCT04736043 on ClinicalTrials.gov |
What this trial studies
This study involves the development of organoids from pancreatic cancer tissue obtained through endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) and biopsy (EUS-FNB) before surgery, as well as from tissue collected post-surgery. The organoids will be tested for their response to various anti-cancer drugs used in adjuvant chemotherapy through cell viability assays. Additionally, genomic analyses will be performed on each organoid to identify unique mutations that may influence drug reactivity. The ultimate goal is to establish a predictive platform that can guide personalized adjuvant chemotherapy strategies for patients after surgery.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with newly diagnosed, resectable pancreatic cancer who are eligible for surgery and require adjuvant chemotherapy.
Not a fit: Patients with relapsed pancreatic cancer or those who are not candidates for surgery will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized treatment plans for patients with resectable pancreatic cancer.
How similar studies have performed: While the use of organoids in cancer treatment prediction is an emerging field, similar studies have shown promise in other types of cancers, indicating potential for success in this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18 years old or older 2. Newly discovered pancreatic cancer and not a relapse 3. Diagnosed with pancreatic cancer via EUS-FNA, EUS-FNB before surgery 4. Patients who can undergo surgery for pancreatic cancer 5. Diagnosed with pancreatic cancer from the final tissue pathology diagnosis after surgery 6. who is in need of adjuvant chemotherapy after surgery 7. Able to make decisions for oneself for participation 8. Has obtained voluntary consent in written form (if 70 years of age or older, receive consent from the guardian as well) Exclusion Criteria: * None
Where this trial is running
Seoul
- Samsung Medical Center — Seoul, Korea, Republic of (Recruiting)
Study contacts
- Study coordinator: Joo Kyung Park, MD
- Email: mdsophie@gmail.com
- Phone: 82-2-3410-3409
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.